pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ELI LILLY CO · news · pharmadog
← back to ELI LILLY CO
News mentioning ELI LILLY CO
230
stories
16h
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
17h
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
1d
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
fiercebiotech
1d
Capricor’s data clash and a fugitive in the C-suite
stat
1d
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
1d
AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal
endpoints
1d
Gerresheimer divests two businesses worth €1.5B; Resilience, Lilly boost injectable pen capacity
endpoints
1d
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
1d
BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this year
fiercebiotech
2d
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
2d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
2d
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
biopharma dive
2d
STAT+: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and more
stat
2d
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
biospace
2d
GSK cost-cutting plan includes global layoffs
biospace
3d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
3d
FDA offers updated guidance for generics of weight loss blockbusters
endpoints
3d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
3d
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
biospace
3d
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
fiercebiotech
4d
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
biospace
4d
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
biospace
4d
Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears
fiercebiotech
5d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
5d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
7d
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
7d
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
endpoints
7d
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
7d
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
7d
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
← prev
page 1 of 8
next →
